Gossamer Bio Inc., a clinical biopharmaceutical company, has announced new compensation terms for three non-executive employees. The company's Compensation Committee has approved the grant of non-qualified stock option awards, allowing the purchase of up to 168,750 shares of Gossamer's common stock under their 2023 Employment Inducement Incentive Award Plan. Effective August 5th, 2025, these options are priced at $2.16 per share, matching the closing price on the Nasdaq Global Select Market on that date. The options have a ten-year term and will vest over four years, with an initial 25% vesting after one year and the rest vesting in monthly installments, contingent upon continued employment with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.